Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

Syed A. Hussain,Pablo Maroto,Miguel Angel Climent,Diletta Bianchini,Robert H. Jones,Chia-Chi Lin,Shian-Shiang Wang,Emma Dean,Kate Crossley,Laura Schlieker,Thomas Bogenrieder,Johann S. de Bono

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

2019

Syed A. Hussain
Pablo Maroto
Miguel Angel Climent
Diletta Bianchini
Robert H. Jones
Chia-Chi Lin
Shian-Shiang Wang
Emma Dean
Kate Crossley
Laura Schlieker
Thomas Bogenrieder
Johann S. de Bono

5030Background: Insulin-like growth factor receptor-1 (IGF-1R) signaling activates the PI3K/AKT pathway and may lead to androgen receptor (AR) transactivation and progression to endocrine treatment...

Keywords:

Castration
Xentuzumab
Prostate cancer
Abiraterone
Oncology
Pathology
Internal medicine
Enzalutamide
Docetaxel
Chemotherapy
Medicine
Androgen receptor
PI3K/AKT/mTOR pathway
Endocrine system
Transactivation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations